Skip to main content

Rheumatoid arthritis


07-06-2019 | Rheumatoid arthritis | Case study | Article

Tofacitinib in a patient with refractory severe rheumatoid arthritis

Paul Emery and John Fitton present the case of a patient who has responded to treatment with the JAK inhibitor tofacitinib as her sixth-line targeted therapy for biologic-refractory rheumatoid arthritis.

03-06-2019 | Rheumatoid arthritis | Highlight | News

IL-6 receptor inhibition may induce bone erosion repair in RA

Patients with early rheumatoid arthritis who are treated with the interleukin-6 receptor inhibitor tocilizumab experience more pronounced repair of bone erosions than those given adalimumab plus methotrexate, indicate findings from the REBONE study.

24-05-2019 | Rheumatoid arthritis | Highlight | News

Opioids, SSRIs, glucocorticoids implicated in RA fracture risk

US research shows that the use of opioids, selective serotonin reuptake inhibitors, or glucocorticoids may increase the risk for all types of osteoporotic fracture in patients with rheumatoid arthritis.

20-05-2019 | Rheumatoid arthritis | Highlight | News

Glucocorticoid use may increase infection risk in RA patients undergoing joint replacement

Analysis of two US administrative databases indicates that glucocorticoid use is associated with a dose-dependent increase in postoperative infection risk in patients with rheumatoid arthritis undergoing elective total knee or hip replacement.

13-05-2019 | Rheumatoid arthritis | Highlight | News

Switch from adalimumab to baricitinib may benefit some RA patients

Analysis of data from the RA-BEAM and RA-BEYOND trials suggests that switching from adalimumab to baricitinib is associated with improvements in disease control and patient-reported outcomes in patients with rheumatoid arthritis, with an acceptable safety profile.

17-04-2019 | Rheumatoid arthritis | Highlight | News

RA flare rates unaffected by tapering strategy

Rheumatoid arthritis flare rates are similar regardless of which drug type is tapered first after achievement of disease control during conventional synthetic DMARD and tumor necrosis factor inhibitor combination therapy, research shows.

02-04-2019 | Rheumatoid arthritis | Highlight | News

Cardiovascular risk associated with conventional, biologic DMARDs characterized

Tocilizumab is associated with a lower risk for major adverse cardiovascular events than tumor necrosis factor inhibitors among patients with rheumatoid arthritis, whereas the use of conventional DMARDs may be linked to an elevated risk, researchers report.

29-03-2019 | Rheumatoid arthritis | Feature | Article

JAK inhibitors in RA: A round-up of the phase III trials

medwireNews summarizes the completed and ongoing phase III trials of JAK inhibitors in patients with rheumatoid arthritis.

22-03-2019 | Rheumatoid arthritis | Highlight | News

Deep learning algorithm shows promise for predicting RA outcomes

Findings from a proof-of-concept study suggest that deep learning models based on electronic health records may be a feasible approach for forecasting disease outcomes in people with rheumatoid arthritis.

04-03-2019 | Rheumatoid arthritis | Highlight | News

Sustained smoking cessation may reduce excess RA risk

Maintaining a nonsmoking status for a sustained period is associated with a reduction in the excess risk for developing seropositive rheumatoid arthritis, findings suggest.

25-02-2019 | Vaccination | Highlight | News

Immunogenicity of influenza vaccine confirmed in patients with rheumatic disease

Influenza vaccination gives rise to an adequate immune response among patients with rheumatic conditions, researchers report.

12-02-2019 | Cardiovascular disease | Editorial | Article

Cardiovascular risk management in arthritis: Why still a bridge too far?

Cardiovascular disease is the main cause of death in patients with rheumatoid arthritis. In this editorial Michael Nurmohamed discusses the EULAR recommendations for cardiovascular risk management, focusing on the role of the rheumatologist.

11-02-2019 | Rheumatoid arthritis | Editorial | Article

20 years of TNF inhibitors in rheumatoid arthritis

Understanding and treatment of rheumatoid arthritis has changed dramatically over the past two decades. Peter Taylor describes the impact of biologic tumor necrosis factor inhibitors on the management of this disease.

31-01-2019 | Rheumatoid arthritis | Highlight | News

Effectiveness of tocilizumab, rituximab over other biologics demonstrated

Patients with rheumatoid arthritis have better outcomes when treated with rituximab or tocilizumab than abatacept or tumor necrosis factor inhibitors, suggest the results from two real-world studies.

16-01-2019 | Rheumatoid arthritis | Highlight | News

Gene expression profiling points to methotrexate nonresponders

Rheumatoid arthritis patients who are unlikely to respond to methotrexate could be identified based on their gene expression profiles before and 4 weeks after initiating treatment, say researchers.

14-01-2019 | Rheumatoid arthritis | Highlight | News

Trial results support management of cardiovascular risk factors in RA patients

Managing traditional cardiovascular risk factors with a treat-to-target approach slows progression of subclinical atherosclerosis among patients with rheumatoid arthritis, suggest results from the FRANCIS trial.

20-12-2018 | Rheumatoid arthritis | Highlight | News

Serum calprotectin predicts relapse risk in TNFi-treated RA, PsA

Serum calprotectin levels independently predict relapse risk in tumor necrosis factor inhibitor-treated patients with rheumatoid arthritis or psoriatic arthritis who are in remission or have low disease activity, Spanish researchers report.

19-12-2018 | Diagnosis and screening | Podcast | Video

The importance of early diagnosis and treatment of inflammatory arthritis

In this Medicine Matters rheumatology podcast, we talk to President-Elect of EULAR Professor Iain McInnes, about the importance of early diagnosis and treatment of rheumatic diseases.

03-12-2018 | Rheumatoid arthritis | Highlight | News

Chronic opioid use rising in RA patients

Chronic opioid use among patients with rheumatoid arthritis increased substantially between 2002 and 2015, researchers report.

15-11-2018 | Etanercept biosimilar | Highlight | News

No worsening in disease activity with switch to biosimilar etanercept

Disease activity does not change following the switch from etanercept to the biosimilar formulation SB4, and treatment retention rates may be determined by patient-specific factors, suggests an analysis of the DANBIO registry.

Image Credits